The company has not filed an annual or quarterly report since its Q3 FY2019 10-Q, filed Oct 30, 2019. Its latest SEC filing is a SC 13G/A from Feb 13, 2020.
10-Q for Q3 FY2019, filed Oct 30, 2019
The sections below describe the company as of the FY2018 annual report.
Provides genomic breast cancer tests that analyze tumor samples to guide treatment decisions, as well as tests for prostate and colon cancers.
10-K for FY2018, filed Feb 28, 2019We offer our tissue-based invasive breast, DCIS, prostate and colon Oncotype DX tests as clinical laboratory services, where we analyze the…View ↗
The Oncotype DX invasive breast cancer test has extensive clinical evidence validating its ability to predict the likelihood of breast…View ↗
The Company operates in one business segment, which primarily focuses on the development and global commercialization of genomic‑based…View ↗
Patients and third-party payors pay for Oncotype testing, and revenue comes when test reports are delivered. Pharmaceutical and biopharmaceutical companies also pay for study work, with revenue coming in as the work is performed.
10-K for FY2018, filed Feb 28, 2019The majority of the Company’s historical product revenues have been derived from the sale of its Oncotype DX breast cancer test. For…View ↗
The Company’s performance obligations are satisfied at the point in time when test reports are delivered. The Company also provides…View ↗
Contract revenues are generally derived from studies conducted with biopharmaceutical and pharmaceutical companies. The specific…View ↗
We depend upon third-party payors, both public and private, to provide reimbursement for our tests. Accordingly, we have and expect to…View ↗
$394.1M
10-K for FY2018, filed Feb 28, 2019
$394.1M ↗
Physicians order tests for cancer patients. Genomic Health sells directly through its commercial presence in the United States and some other countries, and distributors also sell tests outside the United States.
10-K for FY2018, filed Feb 28, 2019
Yes. It kept 7 cents of every revenue dollar as net income in FY2018 and turned 17 cents into free cash flow.
10-K for FY2018, filed Feb 28, 2019
10-K for FY2018, filed Feb 28, 2019
$23.9MView ↗
10-K for FY2018, filed Feb 28, 2019
$25.7MView ↗
10-K for FY2018, filed Feb 28, 2019
$66.5MView ↗
10-Q for Q3 FY2019, filed Oct 30, 2019
$18.7MView ↗
8-K, filed Nov 8, 2019
At the effective time of the Merger on November 8, 2019 (the “Effective Time”), each share of common stock, par value $0.0001 per share, of…View ↗
8-K, filed Jul 30, 2019
On July 28, 2019, Genomic Health, Inc., a Delaware corporation (“Genomic Health”), entered into an Agreement and Plan of Merger (the…View ↗
8-K, filed Jul 29, 2019
Genomic Health Reports 19% Revenue Growth and Record Profit in Second Quarter 2019, Raises Full-Year GuidanceView ↗
Grew. Revenue grew 43% in 4 years, from $275.7M in FY2014 to $394.1M in FY2018, about 9% a year.
Liquid biopsy offering
The earlier report described liquid biopsy tests as planned pipeline products; the later report describes a liquid-based test as commercially available.
10-K for FY2015, filed Mar 9, 2016 10-K for FY2018, filed Feb 28, 2019Our research and development activities are focused on developing a pipeline of tests to optimize the treatment of various cancers…View ↗
Competes with Agendia, BioTheranostics, Exact Sciences, GenomeDx Biosciences, Guardant Health, Hologic, Myriad Genetics, NanoString Technologies, NeoGenomics, OPKO Health, Qiagen, Danaher, Bio-Techne, Grail, MDxHealth, Metamark Genetics, Natera, Personal Genome Diagnostics, Laboratory Corporation of America Holdings, and Quest Diagnostics
10-K for FY2018, filed Feb 28, 2019We compete in a rapidly evolving and highly competitive industry, and there are a number of private and public companies that offer…View ↗
Loading...
